Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells by Kiraz, Yağmur et al.
ORIGINAL ARTICLE
Apoptotic effects of non-edible parts of Punica granatum
on human multiple myeloma cells
Yağmur Kiraz1,2 & Vidushi S. Neergheen-Bhujun3 & Nawraj Rummun3 & Yusuf Baran1,2
Received: 4 June 2015 /Accepted: 20 August 2015 /Published online: 29 August 2015
# International Society of Oncology and BioMarkers (ISOBM) 2015
Abstract Multiple myeloma is of great concern since existing
therapies are unable to cure this clinical condition. Alternative
therapeutic approaches are mandatory, and the use of plant ex-
tracts is considered interesting. Punica granatum and its derived
products were suggested as potential anticancer agents due to the
presence of bioactive compounds. Thus, polypenolic-rich ex-
tracts of the non-edible parts of P. granatum were investigated
for their antiproliferative and apoptotic effects on U266 multiple
myeloma cells.We demonstrated that therewere dose-dependent
decreases in the proliferation of U266 cells in response to
P. granatum extracts. Also, exposure to the extracts triggered
apoptosis with significant increases in loss of mitochondrial
membrane potential inU266 cells exposed to the leaves and stem
extracts, while the flower extract resulted in slight increases in
loss of MMP. These results were confirmed by Annexin-Vanal-
ysis. These results documented the cytotoxic and apoptotic ef-
fects of P. granatum extracts on human U266 multiple myeloma
cells via disruption of mitochondrial membrane potential and
increasing cell cycle arrest. The data suggest that the extracts
can be envisaged in cancer chemoprevention and call for further
exploration into the potential application of these plant parts.
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Introduction
Cancer is a multifactoral disease, with a consequence of the
unusual mechanisms of genetic, metabolic or biochemical fac-
tors, which basically spoil the controlled proliferation and/or
apoptosis mechanism of the cells [1]. The unlimited ability of
proliferation, the developed resistance against apoptotic sig-
nals, the capability of invasion, metastasis and angiogenesis,
abnormal activity of energy metabolism and the defence
against immune attack are the hallmarks of cancer [2, 3].
Each of these characteristic features of cancer cells is used as
targets for different therapies. In addition, tumour cells usually
acquire the ability to evade death by inactivating cell death
pathways that normally function to eliminate damaged and
harmful cells, a feature that often entails the development of
chemotherapeutic resistance encountered during treatment.
An interesting strategy for targeting the cancer cells in-
cludes the use of chemicals, dietary biofactors, phytochemi-
cals and even whole plant extracts to thwart the progress of
cancers by halting/reversing tumor promotion/progression
[4–6]. Previously, the anti-carcinogenetic properties of phyto-
chemicals such as resveratrol, gingerol, caffeic acid phenyl
ester or genistein were established in many different studies.
[7]. Also, since the plant extracts include various types of
metabolite that each of them can target different pathways, it
creates a synergistic response in the cells, which makes the
plant material more preferable for anti-cancer studies.
However, the success of the evaluation of any anticancer
agents depends critically on the interaction of basic, pre-
clinical and clinical research in a cooperated network.
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Punica granatum L., also known as pomegranate, be-
longing Punicaceae family, has been documented to
confer multiple health benefits in ethnomedicine and in
multiple folklore medicinal system, including that of
Mauritius [8–12]. It is known as an anti-bacterial, anti-
diabetic, anti-hypertensive and most importantly anti-
c a r c i n og en i c sub s t a n c e [ 8 ] . Th e s e t ype s o f
metabological effects of P. granatum resulted from its
secondary metabolite ingredients, especially polypheno-
lic composide, which is found at the high level in the
plant [13–16]. Pomegranate has edible and non-edible
parts that include different amounts of phytophenolic
substances which have been studied very commonly
[8, 17, 18].
Pomegranate extract exhibits anticancer activity via in-
hibition of cell growth and survival on the human breast
cancer (MCF-7) line in both time- and dose-dependent
manner [19]. Pomegranate-derived ellagitannins showed
in vitro anti-proliferative and anti-aromatase activity in
breast cancer cells [13], while pomegranate juice con-
sumption revealed a significant prolongation of prostate-
specific antigen doubling time, in both an initial phase II
clinical trial in patient with prostate cancer [20] and a
randomized phase II study [21]. Raw pomegranate peel
extract offers selective cytotoxic activity against
promyelocytic (HL60) cell lines and immune-stimulatory
effect in peripheral blood mononuclear cells [22].
Pomegranate juice extract polyphenols exhibited anti-
leukemic activity by inducing apoptosis and inhibiting
cellular proliferation by inducing S phase arrest in leuke-
mia cell lines [16, 23].
The evaluation of pomegranate non-edible part ex-
tracts in altering the hallmarks of cancer cells is of inter-
est to the scientific community as these parts could be
promoted for use. Nevertheless, understanding the mech-
anisms of action of these extracts is particularly impor-
tant. Thus, this study aimed at investigating the cytotoxic
and apoptotic effects of non-edible parts of the Mauritian
cultivar of pomegranate on U266 cells, with the view of
promoting their utilisation in functional health and che-
moprevention. U266 cells were chosen by considering
their well characterization and convenient culture condi-
tions. In this context, we evaluated the apoptotic effects
of P. granatum leaves, flowers and stem extracts on
U266 multiple myeloma cells by detection of cell prolif-
eration, together with measuring mitochondrial mem-
brane potential, and these results were confirmed by ap-
optotic assays. Cytostatic effects of P. granatum extracts
(leaves, flowers and stem) were established by cell cycle
analysis. Also, considering the lack of literature knowl-
edge on the anticancer effects of P. granatum extracts on
human multiple myeloma cells, this study represents a
pioneer research in this area.
Materials and methods
Plant materials
Pomegranate plant and fruit parts were collected from a do-
mesticated plant growing in a backyard in the Pamplemousses
district of Mauritius Island. The plant parts were collected
during the month of September 2011 and authenticated by
the herbarium of Mauritius Sugar Industry Research
Institute, Réduit. P. granatum leaves, stems, flowers and fruits
were collected from the same plant. The latter were air-dried,
and the samples were homogenised to a fine powder prior to
extraction.
Preparation of extracts
The leaves, stems, flowers and fruit materials of P. granatum
were extracted thrice with 70 % methanol (1:3, w/v) and
allowed to macerate each time at 4 °C for 24 h as described
in Rummun et al. [24]. The filtrates were pooled together and
concentrated in vacuo at 37 °C. The concentrated aqueous
extract was partitioned in dichloromethane to remove fats
and chlorophyll, and the aqueous phase was then collected
and lyophilized. The lyophilized powders, thereof derived,
were dissolved in deionized water and in 100 % methanol to
a concentration of 1 g of air-dried mass to 5 mL for the sub-
sequent tests.
Cell lines and culture conditions
Human multiple myeloma U266 cells were obtained from
American Type Culture Collection (ATCC TIB-196) and cul-
tured in RPMI 1640 growth medium containing 10 % fetal
bovine serum and 1 % penicillin-streptomycin at 37 °C in 5 %
CO2.
Measurement of cell proliferation by MTT assay
Cytotoxic effects of P. granatum leaves, flowers and stem
extracts on U266 cells were determined by MTT proliferation
assay after 48 and 72 h of incubation with increasing concen-
tration of the extracts. Initially, 1×104 cells in 100 μl of medi-
um were seeded in 96-well plates and 1-, 10-, 50-, 100 μg/ml
of P. granatum flower extract, 1-, 10-, 50-, 100-, 500 μg/ml of
P. granatum stem and leaves extracts were applied. Also, as
the control group, cells were treated with no extracts but only
culture media; then, they were incubated at 37 °C in 5 % CO2
for 48 and 72 h. After the incubation period, 20μl ofMTTwas
added and incubated for three more hours. Afterwards, the
plates were centrifuged at 1800 rpm for 10 min, and superna-
tants were removed. MTTcrystals were dissolved in 150 μl of
DMSO per well. Plates were shaken for 10 min at 150 rpm for
homogenisation. Finally, the plates were read at 570 nm
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wavelengths by fluorescence Elisa reader (Thermo Varioscan
Spectrum, Finland), and IC50 values were calculated by the
cell proliferation plots [25].
Determination of the changes in mitochondrial membrane
potential
The loss of mitochondrial membrane potential (MMP) in U266
cells exposed to 1-, 10-, 50- and 100 μg/ml of P. granatum
flower extract and 1, 10, 50, 100 and 500 μg/ml of
P. granatum stem and leaves extracts was determined by JC-1
Mitochondrial Membrane Potential Detection Kit (Cell
Technology, USA). Aswe did inMTT test, for the control group,
cells were treated with no extracts but only culture media. The kit
utilises JC-1, a unique cationic dye that signals the loss of MMP.
In apoptotic cells, MMP collapses and JC-1 dye remains in the
cytoplasm as a monomer, which stains green under fluorescent
light, whereas JC-1 passes and accumulates into the mitochon-
dria and stains red in non-apoptotic cells. Initially, 1×106 cells in
2ml ofmediumwere seeded in six-well plates, and the cells were
exposed to 1-, 10-, 50- and 100 μg/ml of P. granatum flower
extract and 1, 10, 50, 100 and 500 μg/ml of P. granatum stem
and leaves extracts for 48 and 72 h. Then, the cells were collected
by centrifugation at 400g for 10 min and pellets were homoge-
nized by addition of 300 μl medium; 30 μl of JC-1 dye was
added onto the cells and incubated at 37 °C in 5 % CO2 for
30 min. After incubation, they were centrifuged again at 400g
for 10 min, supernatants were removed and pellets were homog-
enized by addition of 200 μl JC-1 assay buffer. An additional
320 μl of the assay buffer was added onto each sample and
homogenized. Then, 100 μl from each of them was transferred
into a 96-well plate as triplicates. In non-apoptotic cells, red form
of aggregates has absorption/emission maxima of 560/595 nm,
while in apoptotic cells the monomeric green form has
absorption/emission maxima of 485/535 nm. The plate was read
under these wavelengths by fluorescence Elisa reader (Thermo
Varioscan Spectrum, Finland). The changes inMMPwere deter-
mined by green/red values calculated for each concentration and
for control groups as well [26].
Analysis of apoptotic cells by Annexin-V-FITC/PI double
staining
Annexin-V/PI double staining was performed to determine
the apoptotic effects of P. granatum extracts on U266 cells,
and the percentage of apoptotic cell population was deter-
mined by flow cytometry. Annexin-V test is assessed based
on determining an early marker of apoptosis, which is the
translocation of phosphatidylserine from the inner membrane
to the outer cell membrane. Briefly, 1×106 cells in 2 ml medi-
um were seeded in six-well plates, and they were treated with
1-, 10-, 50- and 100 μg/ml of P. granatum flower extracts and
1-, 10-, 50-, 100-, 500 μg/ml of P.granatum stem and leaves
extracts for 48 and 72 h, and for the control group, cells were
treated with no extracts but only culture media. The cells were
then washed twice with cold PBS, and pellets were resuspend-
ed in 1 ml of 1X binding buffer. Then, 100 μl of this mixture
was transferred into glass tubes, and 5 μl of Annexin-V-FITC
(50 μg/ml) and 5 μl of propidium iodide (PI, 100 μg/ml) were
added into the tubes. The samples were vortexed gently and
incubated in the dark for 15 min at room temperature.
Afterward, 400 μl of 1X binding buffer was added to each
sample and then analysed by flow cytometry (BD Facscanto
flow cytometry, Belgium) within 1 h [26].
Cell cycle analysis
Amounts of dsDNA were determined by using propidium io-
dide (PI), a DNA-binding dye, by using flow cytometry (BD
Facscanto flow cytometry, Belgium). The amounts of
fragmented DNA in the cells can be determined by the data
obtained and analysed from the flow cytometry. Initially, 1×106
cells in 2ml of mediumwere seeded in six-well plates, and they
were treated with 1-, 10-, 50- and 100 μg/ml of P. granatum
flower extracts and 1-, 10-, 50-, 100-, 500 μg/ml of
P. granatum stem and leaves extracts for 72 h. Likely to previ-
ous apoptotic tests, for the control group, cells were treated with
no extracts but only culture media. After the incubation period,
the cells were centrifuged at 400g for 10 min. Then, the pellets
were resuspended in 1 ml of cold PBS, and the samples were
kept on ice during the follow-up steps. Then, 4 ml of cold
ethanol was added onto the cells while they were vortexed
gently. All the samples were fixed at −20 °C for at least 24 h.
The cells were then centrifuged at 400g for 10 min again, and
the pellet was homogenizedwith 1ml of cold PBS. Afterwards,
cell pellets were resuspended in 1 ml PBS containing 0.1 %
triton X-100. Then, 100μl of RNase Awas added, and the cells
were incubated at 37 °C for 30 min. Finally, 100 μl of PI was
added, and the cells were incubated at room temperature for
15 min before analysing by flow cytometry.
Statistical analyses Statistical significance was determined
by using one-way analysis of variance (ANOVA) for MTT
analyses and two-way ANOVA for JC-1, Annexin-V and cell
cycle analysis. Differences between groups were considered
as significant at a P value of <0.05. Statistical analyses were
performed with GraphPad Prism 6.0 (GraphPad Software,
Inc., San Diego, CA, USA).
Results
P. granatum extracts inhibited proliferation on U266 cells
Cytotoxic effects of P. granatum leaves, flowers and stem
extracts were determined by MTT proliferation assay after
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48 and 72 h of incubation with increasing concentration of the
extracts. The calculated IC50 values of extracts for 48 and 72 h
were 286 and 267 μg/ml , respectively for P. granatum leaves,
41 and 25 μg/ml for P. granatum flowers, respectively, and
305 and 302 μg/ml for P. granatum stem extracts, respectively
(p<0.05) (Fig. 1a, b).
P. granatum leaves, flowers and stem extracts showed
apoptotic effect on U266 cells in a dose-dependent manner
Annexin-V/PI double staining was performed to determine the
apoptotic effects of P. granatum extracts, and the percentage of
apoptotic cell population was determined by flow cytometry.
Annexin-V analysis revealed that there were 13-, 17 and 19-
fold increases in apoptotic cell population of U266 exposed to
50, 100, and 500 μg/ml leaves extract for 72 h, respectively,
while 8-, 13-, and 15-fold increases in apoptotic cell population
of U266 exposed to the same doses for 48 h (Fig. 2a, d). There
were 1.8- and 1.6-fold increases in apoptotic cells exposed to
50 and 100 μg/ml flower extracts for 48 h, while it was four-
and 3.53-fold for 72 h, respectively (Fig. 2b, e). Ten- and 16-
fold increases in apoptotic cell population were determined in
U266 cells exposed to 100 and 500μg/ml stem extract for 48 h,
respectively, while 18- and 27-fold increase in apoptotic cell
population was detected for 72 h of incubation as compared to
control cells (p<0.05) (Fig. 2c, f).
P. granatum leaves, flowers and stem extracts decreased
MMP in U266 cells in a dose-dependent manner
In order to confirm the data obtained by the Annexin test, we
determined the loss of mitochondrial membrane potential in
Fig. 1 Cytotoxic effects of P. granatum flower, leaves and stem extracts
on U266 cells for 48 (a) and 72 h (b). IC50 value was determined from
the cell proliferation plots. The error bars represent the standard
deviations. Statistical significance was determined by using one-way
ANOVA; p<0.05 was considered as significant
Fig. 2 Evaluation of apoptotic U266 cells exposed by P. granatum
extracts. a Apoptotic cells that induced by P. granatum leaves extract
and P. granatum flower and stem extracts, respectively (b, c). Flow
cytometry results are shown in d, e and f, respectively. Cells in the
lower right quadrant indicate Annexin-positive/PI-negative, meaning
early apoptotic cells, while the cells in the upper right quadrant
indicate Annexin-positive/PI-positive, late apoptotic cells. The error
bars represent the standard deviations. Statistical significance was
determined by using two-way ANOVA; p<0.05 was considered as
significant
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U266 cells exposed to increased concentrations of
P. granatum (p<0.05). There were 7.3- and 67.3-fold in-
creases in loss of MMP in response to 250 and 500 μg/ml
concentration of P. granatum leaves extract for 48 h and
70.3- and 226.4-fold increases in loss of MMP in response
to the same concentrations for 72 h, respectively (Fig. 3a).
There were 1.69- and 3.76-fold increases in response to
50 μg/ml P. granatum flower extracts for 48 or 72 h,
Fig. 2 (continued)
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respectively, while 100 μg/ml P.granatum flower extracts ap-
plication increased loss ofMMP for 2.29- or 4.57-fold after 48
or 72 h, respectively (Fig. 3b). On the other hand,
P. granatum stem extract showed 1.66- and 2.52- or
1.37- and 2.45- fold increases in loss of MMP in response
to 250 and 500 μg/ml concentrations for 48 or 72 h, re-
spectively (Fig. 3c).
P. granatum leaves, flowers and stem extracts caused cell
cycle arrest in G2/M and S phases
We determined the cytostatic effects of P. granatum extracts
on MM cells. The leaves extracts increased the percentage of
U266 cells in G2/M phase in a dose-dependent manner. In the
untreated control group, there was 43 % of population in G2/
Fig. 2 (continued)
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M phase, while exposure to 250 μg/ml leaves extract arrested
59% of cells in G2/M phase. There was no differences in the S
phase for the different concentrations used (Fig. 4a, d).
P. granatum flower extract increased U266 cell population
in both G2/M phase and S phase in a dose-dependent manner
(Fig. 4b, e). In the untreated control group, there was 53 % of
Fig. 2 (continued)
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population in G2/M phase, while exposure to 100 μg/ml flow-
er extract arrested 62 % of cells in G2/M phase. On the other
hand, there was 1.7 % of cell population in S in un-
treated control group, while exposure to 100 μg/ml
flower extract arrested 8.6 % of cells in S phase.
Also, there were increases in the population of U266
cells in G2/M phases, but not any substantial difference
for S phases, and decreases in G0/G1 cell population in
response to an increasing concentration of P. granatum
stem extract (Fig. 4c, f). In the untreated control group,
there was 43.8 % of population in G2/M phase, while
exposure to 750 μg/ml stem extract arrested 61.7 % of
cells in G2/M phase.
Discussion
Multiple myeloma is a systemic malignancy of pathologic plas-
ma cells that results in the accumulation of the cancerous cells
in the bones and bone marrow. Current clinical therapies for
Fig 3 Changes in mitochondrial membrane potential in response to
increasing concentration of P. granatum leaves (a), flower (b) and stem
(c) extracts. The error bars represent the standard deviations. Statistical
significance was determined by using two-way ANOVA; p<0.05 was
considered as significant
Fig 4 Effects of P. granatum extracts on cell cycle progression of U266
cells. Percentage of U266 cell population in different cell cycle phases in
response to P. granatum leaves (a), flower (b) and stem (c). Flow
cytometry results are shown in d, e and f, respectively
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multiple myeloma have limited success and are associated with
consequent adverse drug reactions. Although novel agents im-
prove the life quality and survival of patients, most patients will
eventually relapse or become refractory to the treatment, mak-
ing this hematological malignancy incurable [27]. Therefore,
the need to identify alternative therapeutic approaches is man-
datory. This has led to the search of novel bioactive compounds
and/or extracts against multiple myeloma from untapped re-
sources. A plethora of successful anticancer drugs have been
derived from natural plant products [28], and the search for new
anticancer drugs from the plant kingdom is ongoing. In the
same vein, we investigated the cytotoxic and apoptotic effect
of non-edible parts of the Mauritian cultivar of pomegranate on
U266 multiple myeloma cells.
Control
10µg/ml
100µg/ml
500µg/ml
250µg/ml
d
Fig. 4 (continued)
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The MTT proliferation assay revealed that all the non-
edible part extracts of pomegranate tested reduced the survival
of cancerous cells in a dose-dependent manner (Fig. 1a, b).
P. granatum flower extract showed promising anti-
proliferative activity against U266 cells compared to the
leaves and stem extracts. P. granatum leaves extract at the
same concentration tested was however more potent than
P. granatum stem extracts (p<0.05). Furthermore, the flower
extract also inhibited cancerous cell proliferation in a time-
dependent manner, with a calculated IC50 value of 41 and
25 μg/ml for 48 and 72 h of exposure, respectively. The data
highlighted the cytotoxic effect of P. granatum leaves, flowers
and stem against U266 cells. Similarly, Bekir et al. have re-
ported promising cytotoxic activity of pomegranate leaves
Control
1µg/ml
10µg/ml
100µg/ml
50µg/ml
e
Fig. 4 (continued)
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extracts against breast cancer cell line MCF-7, with IC50
values less than 50 mg/l [29].
Lucci et al. has shown the potent antiproliferative activity of
pomegranate seed extract against hormone-dependent human
breast cancer LNCaP, with an IC50 value reported to be three
times lower than vinblastine. In the same study, they also report-
ed the promising antiproliferative activity of pomegranate seed
extract against renal adenocarcinoma ACHN (IC50 value of
26.5 μg/ml), human malignant melanoma A375 (IC50 value of
22.9 μg/ml), human amelanotic melanoma C32 (IC50 value of
15.3 μg/ml), human breast cancer MCF-7 (IC50 value of
9.6 μg/ml) and Caucasian lung large cell carcinoma COR-L23
(IC50 value of 23 μg/ml) [30]. Likewise, Orgil et al. compared
the antiproliferative activity of both edible and non-edible pome-
granate fruit parts against two cancer cell lines (MCF-7 and
LNCaP) and reported the non-edible sections of the fruit to exert
Control
10µg/ml
100µg/ml
500µg/ml
250µg/ml
750µg/ml
f
Fig. 4 (continued)
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highest anti-proliferative activities. The authors further reported
that the bark, fruitless and roots exhibited the highest anti-
proliferative activities. The leaf extract had relatively lower
anti-proliferative activity compared to other plant organs and
about 4.5-fold lower than the root extracts [31]. This studywould
be considered as a basis for further investigation to deepen our
study by determining the anticancer effects of bark, fruitless and
root extracts of P. granatum on multiple myeloma cells.
The potent anti-proliferative activities of the non-edible
pomegranate extracts have been attributed to the high amount
of phenolics present in the extracts [30, 31]. Literature
abounds in examples of the anti-proliferative and anticancer
effect of pomegranate fruit and juice, all of which have been
attributed to the high level of phenolic compounds present
[13, 16, 20, 23, 32–38]. Among the different mechanisms of
action involved, plant phenolics exert chemopreventive activ-
ity via its antioxidative potential [7].
A previous study has reported that the non-edible pome-
granate extracts investigated in the present study are very rich
sources of polyphenolic and also has potent antioxidant activ-
ities [23]. The extracts were obtained bymaceration with 70%
methanol which allowed the extraction of polyphenolic com-
pounds. The polyphenolic contents were highest in flower
extract with the total phenolic content estimated at 336.51±
0.70 mg gallic acid equivalent per gram air dried weight and
total flavonoid content to 213.54±3.14 mg gallic acid equiv-
alent per gram air dried weight. These phytochemicals may
contribute to the potent anti-proliferative activity against
U266 cells, of the flower extract demonstrated in this study.
Induction of apoptosis by plant phytochemicals has been
proposed as a target for cancer prevention [7, 39]. In order to
assess the effects of concentration and exposure time of the
extracts on apoptosis of multiple myeloma cells, the degree of
apoptotic cells was measured by flow cytometry using
Annexin-V/PI double stain. It was found that pomegranate
flower, leaf and stem extracts were able to increasingly induce
apoptosis of the cancerous cells in both concentration- and
time-dependent manner (Fig. 2a, d). When U266 cells were
treated with leaves extract at concentrations of 500 and
1000 μg/ml for 48 h, eightfold and 15-fold increases in apo-
ptotic cell population were achieved, respectively. For the
same tested dose, an exposure time of 72 h resulted in 13-
and 19-fold increases, respectively.
MMP is a marker of mitochondrial membrane permeability,
and MMP decrease could result in the activation of mitochon-
drial pro-apoptotic factors [40]. To determine whether multiple
myeloma cell apoptosis induced by pomegranate extracts was
associatedwithmitochondrialmembrane dysfunction, the loss of
MMP was determined using JC-1 probe. All the tested extracts
decreased the MMP in U266 cells in a dose-dependent manner
(Fig. 3a–c). Pomegranate leaves extracts caused the most signif-
icant loss of MMP potential. The extracts under study may in-
duce apoptosis in U266 cells partly by causing loss of MMP.
However, the flower extract showed only<5 % increase in the
loss of the MMP, thereby indicating that the cytotoxic effect on
the U266 cells may be ascribed to different mechanisms.
Cell cycle analysis indicated that exposure of U266 cells to
the pomegranate extracts resulted in cell cycle arrest at G2/M
phase. However, the flower extract induced an arrest at both
G2/M and S phase in a dose-dependent manner. The check-
points that control G1/S and G2/M transitions act as an inspec-
tionmechanism for the persistence of the cell cycle [41]. Thus,
when an improper action is detected at the cell cycle check-
points, such as uncompleted DNA replication or a mismatch
that cannot be repaired by the cell, apoptotic cascade would be
activated that eventually leads to the death of the cell,
representing one of the ideal strategies for cancer therapy
[42]. Interestingly, we found that G2/M phase arrest of the
U266 cells was observed at the highest stem concentration
followed by 250 μg/ml leaves extracts (Fig. 4a–f).
Nevertheless, the molecular mechanisms of pomegranate
extract-induced cell cycle arrest in these cells require further
investigation.
Conclusion
Treatment of U266 cells with the non-edible pomegranate
extracts significantly reduced cell proliferation/viability and
induced cell death in a dose-dependent manner compared with
that in the untreated control. The induced growth inhibition
appeared to be associated with triggering of apoptosis partic-
ularly for the cells treated with the leaves and stem extracts. In
summary, our data demonstrate that the pomegranate leaves,
stem and flower extracts modulate cell cycle progression and
induce apoptosis in human multiple myeloma cancer cells
through G2/M and S phase cell cycle arrest and mitochondrial
membrane permeabilization. These observations suggest an
anticancer activity of these extracts and prompt for further
investigation into the application of the latter in functional
health and cancer chemoprevention.
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